Immune responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination

Aging and Disease

Volumn 3, Issue 1, 2012, Pages 51-67

  Westerink, M A Julie ^a,b   Schroeder, Harry W ^c   Nahm, Moon H ^d  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Department of Medical Microbiology and Immunology ^*  (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Aging; Antibody repertoire; B cells; Pneumococcus; Vaccine

Indexed keywords

STREPTOCOCCUS PNEUMONIAE;

EID: 84862632799     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (207)

1. Gray BM MD (2008) The history of pneumococcal disease. In Pneumococcal Vaccines: The Impact of Conjugate Vaccine. (Siber G, K. K., Makel P, ed) pp. 3-17, ASM Press, Washington DC
2. Avery OTaWFG (1929). Chemo-immunological studies on conjugated carbohydrate proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med, 50: 533-550
3. Henrichsen J (1995). Six newly recognized types of Streptococcus pneumoniae. Journal of Clinical Microbiology, 33: 2759-2762
4. Park IH, Park S, Hollingshead SK and Nahm MH (2007). Genetic basis for the new pneumococcal serotype, 6C. Infect Immun, 75: 4482-4489
5. (1997). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 46: 1-24
6. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH and Schuchat A (2003). Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med, 348: 1737-1746
7. Breiman RF, Spika JS, Navarro VJ, Darden PM and Darby CP (1990). Pneumococcal bacteremia in Charleston county, South Carolina. A decade later. Arch Intern Med, 150: 1401-1405
8. WHO (2007). Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Wkly Epidemiol Rec, 82: 93-104
9. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R and Keegan E (2002). Pneumococcal serotypes from acute otitis media in rural Kentucky. Pediatr Infect Dis J, 21: 859-865
10. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R and Keegan E (2004). Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J, 23: 829-833
11. Fletcher MA and Fritzell B (2007). Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine, 25: 2507-2512
12. McEllistrem MC, Adams JM, Patel K, Mendelsohn AB, Kaplan SL, Bradley JS, Schutze GE, Kim KS, Mason EO and Wald ER (2005). Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis, 40: 1738-1744
13. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K and Parkinson A (2007). Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA, 297: 1784-1792
14. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ and Pallares R (2008). Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis, 46: 174-182
15. Ruiz-Gonzalez A, Falguera M, Nogues A and Rubio-Caballero M (1999). Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med, 106: 385-390
16. Venkatesan P, Gladman J and Macfarland JT (1990). A hospital study of community acquired pneumonia in the elderly. Thorax, 45: 254-258.
17. Marrie TJ, Durant H and Yates L (1989). Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis, 11: 586-599
18. Marston BJ, Plouffe JF, File TM, Jr., Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS and Breiman RF (1997). Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med, 157: 1709-1718
19. Bartlett JG and Mundy LM (1995). Community-acquired pneumonia. N Engl J Med, 333: 1618-1624
20. Mufson MA, Oley G and Hughey D (1982). Pneumococcal disease in a medium-sized community in the United States. JAMA, 248: 1486-1489
21. Schwartz JS (1982). Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med, 96: 208-220
22. Filice GA, Darby CP and Fraser DW (1980). Pneumococcal bacteremia in Charleston County, South Carolina. Am J Epidemiol, 112: 828-835
23. Sims RV, Boyko EJ, Maislin G, Lipsky BA and Schwartz JA (1992). The role of age in susceptibility to pneumococcal infections. Age ageing, 21: 357-361
24. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcels V, Margolis A, Adair RK and Clemens JD (1991). The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Engl J Med, 325: 1453-1460
25. Watt JP, O'Brien KL, Benin AL, Whitney CG, Robinson K, Parkinson AJ, Reid R and Santosham M (2004). Invasive pneumococcal disease among Navajo adults, 1989-1998. Clin Infect Dis, 38: 496-501
26. Dahl MS, Trollfors B, Claesson BA, Brandberg LL and Rosengren A (2001). Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years. Scand J Infect Dis, 33: 667-672
27. Harrison LH, Dwyer DM, Billmann L, Kolczak MS and Schuchat A (2000). Invasive pneumococcal infection in Baltimore, Md: implications for immunization policy. Arch Intern Med, 160: 89-94
28. Pastor P, Medley F and Murphy TV (1998). Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin Infect Dis, 26: 590-595
29. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B,Patterson J, Zell ER, Schuchat A and Whitney CG (2001). Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. Jama, 285: 1729-1735
30. O'Brien KL, Walters MI, Sellman J, Quinlisk P, Regnery H, Schwartz B and Dowell SF (2000). Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis, 30: 784-789
31. McCullers JA and Bartmess KC (2003). Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis, 187: 1000-1009
32. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, Schaffner W, Craig AS and Griffin MR (2005). Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med, 118: 285-291
33. Morens DM, Taubenberger JK and Fauci AS (2008). Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis, 198: 962-970
34. Sanders LA, Rijkers GT, Kuis W, Tenbergen-Meekes AJ, de Graeff-Meeder BR, Hiemstra I and Zegers BJ (1993). Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol, 91: 110-119
35. Cunningham-Rundles C and Bodian C (1999). Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol, 92: 34-48
36. Johnston DT, Mehaffey G, Thomas J, Young KR, Jr., Wiener H, Li J, Go RC and Schroeder HW, Jr. (2006). Increased frequency of HLA-B44 in recurrent sinopulmonary infections (RESPI). Clin Immunol, 119: 346-350
37. Schroeder HW, Jr., Schroeder HW, 3rd and Sheikh SM (2004). The complex genetics of common variable immunodeficiency. J Investig Med, 52: 90-103
38. Stiehm ER (2008). The four most common pediatric immunodeficiencies. J Immunotoxicol, 5: 227-234
39. Styrt B (1990). Infection associated with asplenia: risks, mechanisms, and prevention. Am J Med, 88: 33N-42N
40. Wara DW (1981). Host defense against Streptococcus pneumoniae: the role of the spleen. Rev Infect Dis, 3: 299-309
41. Redd SC, Rutherford III GW, Sande MA, Lifson AR, Hadley WK, Facklam RR and Spika JS (1990). The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. 1990, 162: 1012-1017
42. Boschini A, Smacchia C, Di Fine M, Schiesari A, Ballarini P, Arlotti M, Gabrielli C, Castellani G, Genova M, Pantani P, Lepri AC and Rezza G (1996). Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis, 23: 107-113
43. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, Davenny K and Friedland GH (1992). Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med, 327: 1697-1703
44. Schuchat A, Broome CV, Hightower A, Costa SJ and Parkin W (1991). Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. Jama, 265: 3275-3279
45. Janoff EN, Breiman RF, Daley CL and Hopewell PC (1992). Pneumococcal disease during HIV infection. Epidemiologic, clinical and immunologic perspectives. Ann Intern Med, 117: 314-324
46. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL and Vugia DJ (2000). Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med, 132: 182-190
47. Dworkin MS, Ward JW, Hanson DL, Jones JL and Kaplan JE (2001). Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis, 32: 794-800
48. Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Linares J and Gudiol F (2005). Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med, 165: 1533-1540
49. Feikin DR, Feldman C, Schuchat A and Janoff EN (2004). Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis, 4: 445-455
50. Lopez-Palomo C, Martin-Zamorano M, Benitez E, Fernandez-Gutierrez C, Guerrero F, Rodriguez-Iglesias M and Giron-Gonzalez JA (2004). Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol, 72: 517-524
51. Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR and Schuchat A (2005). Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis, 191: 2038-2045
52. Cole R (1913). Treatment of pneumonia by means of specific serums. JAMA, 61: 663-666
53. Breiman RF, Butler JC, Tenover FC, Elliott JA and Facklam RR (1994). Emergence of drug-resistant pneumococcal infections in the United States. Jama, 271: 1831-1835.
54. Lynch JP, 3rd and Zhanel GG (2009). Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med, 30: 210-238
55. Plouffe JF, Breiman RF and Facklam RR (1996). Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. Jama, 275: 194-198
56. Austrian R (1986). Some aspects of the pneumococcal carrier state. J Antimicrob Chemother, 18 Suppl A: 35-45
57. Gray BM, Converse GM, 3rd and Dillon HC, Jr. (1980). Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis, 142: 923-933
58. Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW, Mitchell TJ, Hansman D and Paton JC (1994). Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun, 62: 5683-5688
59. Butler JC, Shapiro ED and Carlone GM (1999). Pneumococcal vaccines: history, current status, and future directions. Am J Med, 107: 69S-76S
60. Musher DL, Johnson Jr B and Watson DA (1990). Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay of radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun, 58: 3871-3876.
61. Bruyn GA, Zegers BJ and van Furth R (1992). Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis, 14: 251-262
62. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S and Reid RDW (1976). Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians, 89: 184-194.
63. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ and Hilleman MR (1977). Protective efficacy of pneumococcal polysaccharide vaccines. Jama, 238: 2613-2616
64. Broome CV and Facklam RR (1981). Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the United States. Rev Infect Dis, 3: 277-281
65. Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, Makela PH, Broome CV, Facklam RR, Tiesjema RH et al. (1983). Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis, 148: 1136-1159
66. Austrian R (1981). Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis, 3: S1-17.
67. MacLeod CM, Hodges RG, Heidelberger M and Bernhard WG (1945). Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med, 82: 445-465.
68. Smith AH (1976). The effects of age on the immune response to type III pneumococcal polysaccharide (SIII) and bacterial lipopolysaccharide (LPS) in BALB/c, SJL/J and C3H mice. J Immunol, 116: 469
69. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS et al. (1986). Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med, 315: 1318-1327
70. Hirschmann JV and Lipsky BA (1994). The pneumococcal vaccine after 15 years of use [see comments]. Arch Intern Med, 154: 373-377
71. Fein AM, Feinsilver SH and Niederman MS (1991). Atypical manifestations of pneumonia in the elderly. Clin Chest Med, 12: 319-336
72. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK and Thompson WW (2003). Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med, 348: 1747-1755
73. Moore RA, Wiffen PJ and Lipsky BA (2000). Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract, 1: 1
74. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP and Cucherat M (2001). Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine, 19: 4780-4790
75. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS and Kapoor WN (1994). Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med, 154: 2666-2677
76. Watson L, Wilson BJ and Waugh N (2002). Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine, 20: 2166-2173
77. George JF, Jr. Schroeder HW, Jr. (1992). Developmental regulation of D beta reading frame and junctional diversity in T cell receptor-beta transcripts from human thymus. J Immunol, 148: 1230-1239
78. Schroeder HW, Jr. (2006). Similarity and divergence in the development and expression of the mouse and human antibody repertoires. Dev Comp Immunol, 30: 119-135
79. Timens W, Boes A, Rozeboom-Uiterwijk T and Poppema S (1989). Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol, 143: 3200-3206
80. Kayhty H and Eskola J (1996). New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis, 2: 289-298
81. Black SB, Shinefield HR, Fireman B, Hiatt RA, Polen M and Vittinghoff E (1991). Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61080 children. Pediatr Infect Dis J, 10: 97-104
82. Stein KE (1992). Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis, 165(suppl 1): S49-52
83. Lee CJ (1987). Bacterial capsular polysaccharides--biochemistry, immunity and vaccine. Mol Immunol, 24: 1005-1019
84. VanDam JE, Fleer A and H S (1990). Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie van Leeuwenhoek, 58: 1-47
85. Finland M and Barnes MW (1977). Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J Clin Microbiol, 5: 154-166
86. (2000). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 49: 1-35
87. Hausdorff WP, Siber, G., Paradiso, P.R. (2001). Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. The Lancet, 357: 950-952
88. Hausdorff WP, Bryant J, Paradiso PR and Siber GR (2000). Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis, 30: 100-121
89. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R and Edwards K (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J, 19: 187-195
90. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J and Hackell J (2002). Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J, 21: 810-815
91. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E and Ray P (2003). Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J, 22: 10-16
92. Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, Barth RD, Nuorti JP and Griffin MR (2007). Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics, 119: 707-715
93. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM and Griffin MR (2006). National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics, 118: 865-873
94. Zhou F, Shefer A, Kong Y and Nuorti JP (2008). Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics, 121: 253-260
95. Dagan R, Muallem, M., Melamed, R., Leroy, O., and Yagupsky, P. (1997). Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diptheria toxoid. Pediatr Infect Dis J, 16: 1060-1064
96. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P and Fraser D (2002). Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis, 185: 927-936
97. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N and Yagupsky P (1996). Reduction of nasopharyngeal carriage of pneumocci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis, 174: 1271-1278
98. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I and Klugman KP (1999). Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis, 180: 1171-1176
99. Obaro SK, Adegbola RA, Banya WA and Greenwood BM (1996). Carriage of pneumococci after pneumococcal vaccination. Lancet, 348: 271-272.
100. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG and Moore MR (2010). Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis, 201: 32-41
101. Walter ND, Taylor TH, Jr., Dowell SF, Mathis S and Moore MR (2009). Holiday spikes in pneumococcal disease among older adults. N Engl J Med, 361: 2584-2585
102. Brueggemann AB, Pai R, Crook DW and Beall B (2007). Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog, 3: e168
103. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM and Whitney CG (2007). Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis, 196: 1346-1354
104. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petit S, Reingold A, Schaffner W, Thomas A, Whitney CG and Harrison LH (2009). Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med, 360: 244-256
105. Ongkasuwan J, Valdez TA, Hulten KG, Mason EO, Jr. and Kaplan SL (2008). Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics, 122: 34-39
106. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, Huang SS, Goldstein R and Hanage WP (2007). Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J, 26: 468-472
107. Pichichero ME and Casey JR (2007). Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA, 298: 1772-1778
108. Esteva C, Selva L, de Sevilla MF, Garcia-Garcia JJ, Pallares R and Munoz-Almagro C (2011). Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989-2008). Clin Microbiol Infect
109. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC and Nahm MH (2007). Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol, 45: 1225-1233
110. Leach AJ, Morris PS, McCallum GB, Wilson CA, Stubbs L, Beissbarth J, Jacups S, Hare K and Smith-Vaughan HC (2009). Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis, 9: 121
111. Millar EV, Pimenta FC, Roundtree A, Jackson D, Carvalho Mda G, Perilla MJ, Reid R, Santosham M, Whitney CG, Beall BW and O'Brien KL (2010). Pre- and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis, 51: 1258-1265
112. Nahm MH, Lin J, Finkelstein JA and Pelton SI (2009). Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis, 199: 320-325
113. Sa-Leao R, Nunes S, Brito-Avo A, Frazao N, Simoes AS, Crisostomo MI, Paulo AC, Saldanha J, Santos-Sanches I and de Lencastre H (2009). Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect, 15: 1002-1007
114. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, Trzcinski K, Bruin JP, van Alphen L, van der Ende A and Sanders EA (2010). Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA, 304: 1099-1106
115. Nuorti JP and Whitney CG (2010). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 59: 1-18
116. (2008). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep, 57: 343-344
117. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR and Whitney CG (2005). Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA, 294: 2043-2051
118. (2005). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep, 54: 893-897
119. (2010). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep, 59: 1102-1106
120. Artz A, Ershler W and Longo D (2003). Pneumococcal vaccination and revaccination of older adults. Clinical Microbiology Reviews, 16: 308
121. Torling J, Hedlund J, Konradsen HB and Ortqvist A (2003). Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine, 22: 96-103
122. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD and Silber JL (2010). Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis, 201: 516-524
123. Artenstein MS and Brandt BL (1975). Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J Immunol, 115: 5-7
124. Hammitt LL, Bulkow LR, Singleton RJ, Pekka Nuorti J, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, Rudolph K and Hennessy TW (2011). Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness. Vaccine, 29: 2287-2295
125. (2007). Recommended Adult Immunization Schedule - United States, October 2007 - September 2008. MMWR, 56: Q1-Q4
126. [2008(] Adult Prevention and Treatment of Opportunisitic Infections Guidelines Working Group. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [DRAFT]. June 18, 2008; pp1-289.
127. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH and Chang SC (2004). Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine, 22: 2006-2012
128. Powers DC, Anderson EL, Lottenbach K and Mink CM (1996). Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis, 173: 1014-1018
129. Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M and Treanor JJ (1997). Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun, 65: 242-247
130. Wuorimaa T, Kayhty H, Leroy O and Eskola J (2001). Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine, 19: 1863-1869
131. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R and Miller E (2009). The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis, 49: 1318-1325
132. Lazarus R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D and Pollard AJ (2011). A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis, 52: 736-742
133. Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J and Parkinson AJ (2009). Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis, 49: 241-248
134. Musher DM, Sampath R and Rodriguez-Barradas MC (2011). The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis, 52: 633-640
135. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, Kayhty H, Jonsdottir I and Nahm MH (2003). Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol, 10: 514-519
136. Concepcion NaF, C. (2001). Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbant assay. Clinical and Diagnostic Laboratory Immunology, 8: 266-272
137. Yu X, Sun Y, Frasch C, Concepcion N and Nahm MH (1999). Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol, 6: 519-524
138. Lee H, Nahm MH, Burton R and Kim KH (2009). Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol, 16: 376-381
139. Yu X, Gray B, Chang S, Ward JI, Edwards KM and Nahm MH (1999). Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis, 180: 1569-1576
140. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D and Nahm MH (2006). Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol, 13: 165-169
141. Burton RL and Nahm MH (2006). Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol, 13: 1004-1009
142. Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, Chang I and Cherian T (2003). Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine, 21: 3265-3272
143. Lee LH, Frasch CE, Falk LA, Klein DL and Deal CD (2003). Correlates of immunity for pneumococcal conjugate vaccines. Vaccine, 21: 2199-2205
144. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N and Pierce N (2003). A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med, 349: 1341-1348
145. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, Chang I, Kohberger R, Siber G and Santosham M (2003). Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet, 362: 355-361
146. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P and Kohberger R (2007). Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine, 25: 3816-3826
147. Henckaerts I, Goldblatt D, Ashton L and Poolman J (2006). Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol, 13: 356-360
148. Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA and Henckaerts I (2009). Evaluation of pneumococcal polysaccharide immunoassays using 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol
149. Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH and St Clair EW (2007). Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol, 123: 235-243
150. Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, Hildreth SW and Hill HR (2002). A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am. J. Clin. Pathol., 117: 589-596
151. Fattal-German M, Taillandier J, Mathieu D and Bizzini B (1991). Pneumococcal vaccination of elderly individuals. Vaccine, 9: 542-544
152. Lee H, Nahm MH and Kim KH (2010). The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis, 10: 60
153. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, Plikaytis BD and Carlone GM (1999). Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity [see comments]. Clin Infect Dis, 29: 281-288
154. Rubins JB, et al. (1998). Magnitude, Duration, Quality, and Function of Pneumococcal Vaccine Responses in Elderly Adults. Journal of Infectious Diseases, 178: 431-440
155. Rubins JB, et al. (1999). Determination of Antibody Responses of Elderly Adults to All 23 Capsular Polysaccharides after Pneumococcal Vaccination. Infection and Immunity, 67: 5979-5984
156. Rubins JB and Janoff EN (2001). Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging, 18: 305-311
157. Sankilampi U, Honkanen, P.O., Bloigu, A., Leinonen, M. (1997). Persistence of Antibodies to Pneumococcal Capsular Polysaccharide Vaccine in the Elderly. Journal of Infectious Diseases, 176: 1100-1104
158. Schenkein JG, Park S and Nahm MH (2008). Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine, 26: 5521-5526
159. Hedlund JU, Kalin ME, Örtqvist AB and Hebrichsen J (1994). Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med, 154: 1961-1965.
160. Roghmann KJ, Tabloski PA, Bentley DW and Schiffman G (1987). Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. J Gerontol, 42: 265-270
161. Sankilampi U, Honkanen PO, Bloigu A, Herva E and Leinonen M (1996). Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis, 173: 387-393
162. Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JB, Baughn RE and Mufson MA (1993). Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis, 17: 66-73
163. Kim P, Chung E, Yamashita H, Hung KE, Mizoguchi A, Kucherlapati R, Fukumura D, Jain RK and Yun SH (2010). In vivo wide-area cellular imaging by side-view endomicroscopy. Nat Methods, 7: 303-305
164. Usinger WR and Lucas AH (1999). Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun, 67: 2366-2370
165. Sun Y, Hwang Y and Nahm MH (2001). Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B. Infect Immun, 69: 336-344
166. Scott MG, Crimmins DL, McCourt DW, Chung G, Schable KF, Thiebe R, Quenzel EM, Zachau HG and Nahm MH (1991). Clonal characterization of the human IgG antibody repertoire to Haemphilus influenzae type b polysaccharide: IV. The less frequently expressed VL are heterogenous. J Immunol, 147: 4007-4013
167. Nahm MH, Kim KH, Anderson P, Hetherington SV and Park MK (1995). Functional capacities of clonal antibodies to Haemophilus influnzae type b polysaccharide. Infect Immunity, 63: 2989-2994
168. Lucas AH and Granoff DM (1995). Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol, 154: 4195-4202
169. Granoff DM, Schackelford PG, Holmes SJ, Group. TCVS and Lucas AH (1993). Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates: Description of a new l light chain associated idiotype, and the relation between idiotype expression, avidity and vaccine formulation. J Clin Invest, 91: 786-796
170. Zhong Z, Burns T, Chang Q, Carroll M and Pirofski L (1999). Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect Immun, 67: 4119-4127
171. Shaw DR, Kirkham P, Schroeder HW, Jr., Roben P and Silverman GJ (1995). Structure-function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Ann N Y Acad Sci, 764: 370-373
172. Park MK, Sun Y, Olander JV, Hoffmann JW and Nahm MH (1996). The repertoire of human antibodies to the carbohydrate capsule of Streptococcus pneumoniae 6B. J Infect Dis, 174: 75-82
173. Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK and Goldblatt D (2000). Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol, 30: 1214-1223
174. Lucas AH, Moulton KD, Tang VR and Reason DC (2001). Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F. Infect Immun, 69: 853-864
175. Zhou J, Lottenbach KR, Barenkamp SJ, Lucas AH and Reason DC (2002). Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun, 70: 4083-4091
176. Zhou J, Lottenbach KR, Barenkamp SJ and Reason DC (2004). Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect Immun, 72: 3505-3514
177. Chang Q, Zhong Z, Lees A, Pekna M and Pirofski L (2002). Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect Immun, 70: 4977-4986
178. Russell ND, Corvalan JR, Gallo ML, Davis CG and Pirofski L (2000). Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect Immun, 68: 1820-1826
179. Kolibab K, Smithson SL, Rabquer B, Khuder S and Westerink MA (2005). Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun, 73: 7465-7476
180. Ruben FL and Uhrin M (1985). Specific Immunoglobulin-Class antibody responses in the elderly before and after 14-valent pneumoncoccal vaccine. J Infect Dis, 151: 845-849
181. Pollack M, Koles NL, Preston MJ, Brown BJ and Pier GB (1995). Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect Immun, 63: 4481-4488
182. Raff HV, Bradley C, Brady W, Donaldson K, Lipsich L, Maloney G, Shuford W, Walls M, Ward P, Wolff E et al. (1991). Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. J Infect Dis, 163: 346-354
183. Shyur SD, Raff HV, Bohnsack JF, Kelsey DK and Hill HR (1992). Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci. J Immunol, 148: 1879-1884
184. Taborda CP and Casadevall A (2001). Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol, 166: 2100-2107
185. Park S and Nahm MH (2011). Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun, 79: 314-320
186. Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K and Agematsu K (2005). Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol, 175: 3262-3267
187. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, Berner R, Peters A, Boehm T, Plebani A, Quinti I and Carsetti R (2003). Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med, 197: 939-945
188. Wardemann H, Boehm T, Dear N and Carsetti R (2002). B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J Exp Med, 195: 771-780
189. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Steiniger B, Staudt LM, Casanova JL, Reynaud CA and Weill JC (2004). Human blood IgM memory B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood, 104: 3647-3654
190. Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, Plebani A, Aiuti F and Quinti I (2005). The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol, 115: 412-417
191. Zandvoort A and Timens W (2002). The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol, 130: 4-11
192. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC and Wardemann H (2006). A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med, 203: 393-400
193. Takizawa M, Sugane K and Agematsu K (2006). Role of tonsillar IgD+CD27+ memory B cells in humoral immunity against pneumococcal infection. Hum Immunol, 67: 966-975
194. Moens L, Wuyts M, Meyts I, De Boeck K and Bossuyt X (2008). Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J Immunol, 181: 5306-5312
195. Haas KM, Poe JC, Steeber DA and Tedder TF (2005). B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity, 23: 7-18
196. Taillardet M, Haffar G, Mondière P, Asensio MJ, Gheit H, Burdin N, Defrance T and Genestier L (2009). The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood, 114: 4432-4440
197. Berland R and Wortis HH (2002). Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol, 20: 253-300
198. Hardy RR and Hayakawa K (2001). B cell development pathways. Annu Rev Immunol, 19: 595-621
199. Mackenzie LE, Youinou PY, Hicks R, Yuksel B, Mageed RA and Lydyard PM (1991). Auto- and polyreactivity of IgM from CD5+ and CD5- cord blood B cells. Scand J Immunol, 33: 329-335
200. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA and Chen J (2000). B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med, 192: 271-280
201. Boes M, Prodeus AP, Schmidt T, Carroll MC and Chen J (1998). A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med, 188: 2381-2386
202. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J and Barletta R (1981). Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med, 153: 694-705
203. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H and Zinkernagel RM (1999). Control of early viral and bacterial distribution and disease by natural antibodies. Science, 286: 2156-2159
204. Veneri D, Franchini M, Vella A, Tridente G, Semenzato G, Pizzolo G and Ortolani R (2007). Changes of human B and B-1a peripheral blood lymphocytes with age. Hematology, 12: 337-341
205. Veneri D, Ortolani R, Franchini M, Tridente G, Pizzolo G and Vella A (2009). Expression of CD27 and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus, 7: 29-34
206. Youinou P, Jamin C and Lydyard PM (1999). CD5 expression in human B-cell populations. Immunol Today, 20: 312-316
207. Griffin DO, Holodick NE and Rothstein TL (2011). Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med, 208: 67-80